Sign Up to like & get
recommendations!
0
Published in 2023 at "Hematological oncology"
DOI: 10.1002/hon.3172
Abstract: Zanubrutinib has been approved for the treatment of patients with different lymphoproliferative disorders, and now represents a major breakthrough in the treatment of patients resistant or relapsing after the recommended therapies. Because few systematic studies…
read more here.
Keywords:
clinical needs;
use zanubrutinib;
zanubrutinib;
unmet clinical ... See more keywords